Rhinomed Limited
RHNMF
Other OTC0.02
USD
+0.00
- -
ISIN
AU000000RNO1
Return %
Stock
S&P500
1Y
-68.54
17.85
3Y
-79.35
64.56
5Y
-82.73
69.89
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Johnson
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 132 Gwynne Street Cremorne VIC Australia 3121
- IPO Date
- May 12, 2017
- Website
- rhinomed.global
- Similar Companies
- Business
- Rhinomed Limited is a Melbourne, Australia-based medical technology company specializing in nasal, respiratory, and breathing management technologies. The company manufactures and commercializes a patented nasal and respiratory technology platform designed to enhance respiration, sleep quality, diagnosis of upper respiratory diseases, and nasal drug delivery. Key products include the Turbine, a device aimed at sports performance enhancement; the Mute Nasal Dilator and Mouth Tape, which target the global sleep and snoring market; and the Pronto range designed to address nasal congestion and sleep disturbances. Rhinomed also develops applications for drug delivery, including medical cannabis and treatments for conditions such as anxiety, pain, allergies, nausea, and colds. Its products are Class 1 medical devices approved in major markets, including the US, Europe, Australia, and Canada, and are distributed worldwide through retail networks such as Walgreens, CVS, Boots, Chemist Warehouse, Wizard Pharmacy, and Amazon. Founded in 2002 and headquartered in Melbourne, Rhinomed operates in the sport, sleep, wellness, and drug delivery market segments with a global footprint covering the US, Europe, Australia, and Canada. The company has a portfolio protected by over 50 patents, underscoring its technological innovation in wearable nasal medical devices. Recent major developments include a fully underwritten rights issue in 2024 to raise approximately A$3.54 million, supporting the company's aggressive growth strategy focused on expanding the retail presence of its Mute Nasal Dilator and newly launched Mouth Tape. The company is advancing regulatory approvals for its Rhinoswab diagnostic and rapid antigen testing products and is progressing toward breakeven and profitability through operational optimization. Additionally, Rhinomed has achieved milestones such as significant expansion in US and Australian pharmacy networks and aims to build and own the sleep/snoring category globally, with ongoing efforts to grow e-commerce presence and expand into new geographic markets including the EU. Rhinomed's management team comprises experienced professionals from biotech, medical, consumer health, and global consumer goods industries. The company remains committed to delivering high-margin revenue growth anchored by innovation and expanding distribution across existing and new retail channels worldwide.